Eric Coldwell
Stock Analyst at Baird
(3.74)
# 698
Out of 5,152 analysts
166
Total ratings
61.32%
Success rate
4.33%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Outperform | $19 → $16 | $9.92 | +61.29% | 10 | Feb 27, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $313 → $326 | $275.92 | +18.15% | 15 | Feb 18, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $44.05 | +8.97% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $931.35 | -0.47% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $181.32 | +9.75% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $178.50 | +44.54% | 19 | Oct 29, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $110.60 | +102.53% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $203.98 | -4.89% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $216.02 | -6.03% | 13 | Aug 13, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $469.38 | +4.39% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $9.60 | +66.67% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $61.64 | -27.00% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $78.69 | -16.13% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.85 | +5,309.22% | 4 | Nov 10, 2017 |
Fortrea Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $19 → $16
Current: $9.92
Upside: +61.29%
Labcorp Holdings
Feb 18, 2026
Maintains: Outperform
Price Target: $313 → $326
Current: $275.92
Upside: +18.15%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $44.05
Upside: +8.97%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $931.35
Upside: -0.47%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $181.32
Upside: +9.75%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $178.50
Upside: +44.54%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $110.60
Upside: +102.53%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $203.98
Upside: -4.89%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $216.02
Upside: -6.03%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $469.38
Upside: +4.39%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $9.60
Upside: +66.67%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $61.64
Upside: -27.00%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $78.69
Upside: -16.13%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.85
Upside: +5,309.22%